History
The Narrative Arc
In the four years since Supreme listed on AIM in February 2021, management has run three different strategies under the same logo: a five-division FMCG distributor (FY21–22), a vaping pure-play in waiting (FY23–24), and — once the disposable-vape ban arrived — a re-diversified consumer-brands roll-up (FY25–26). Operationally the team has executed: revenue grew 2.5x to £231m, Adjusted EBITDA more than doubled, and the FY24 ElfBar/Lost Mary windfall was caught and extracted before regulation closed it. But the narrative discipline is weaker. The dividend policy was halved within eighteen months of IPO, the FY23 print badly missed initial expectations, the "longer-term plan to retain" T-Juice ended seven months later, and "international expansion" has been promised every year and delivered in none. Credibility has been built on M&A execution, not on keeping the story straight.
Annotated timeline
Three strategies, one CEO. Sandy Chadha owned 57% at IPO and has navigated each pivot. The pattern: identify a category tailwind, scale fast through bolt-on M&A, then re-pivot when the tailwind ends. It has worked financially. It has not produced a stable story.
What Management Emphasized — and Then Stopped Emphasizing
Reading the CEO reviews and risk sections back-to-back, three themes carried the IPO story, and three different themes carry the story today. The intensity heat-map below codes how often each theme appeared as a primary driver in the strategic report and CEO commentary.
Theme intensity by year (3 = primary driver, 0 = absent).
The dropped themes. The HFSS regulation tailwind was a centrepiece of the FY22 narrative (Battle Bites was "expected to drive sales as retailers seek to replace chocolate"). It vanishes from FY24 commentary. Branded Household Consumer Goods went from a category with growth potential to "non-core" before being repurposed as the reporting line for ElfBar. International expansion has been a stated growth pillar in every annual report from FY21 to FY24 — but the FY25 report removed it from the strategic priorities list, replacing it with "transformational M&A".
The "95% safer than smoking" framing, which appeared verbatim three times in the FY21–22 reports, has gradually been displaced by "credible, sustainable smoking cessation tool". The shift coincides with rising regulatory scrutiny — management did not abandon vaping, but quietly de-coupled the marketing language from the public-health claim.
Risk Evolution
The risk register tells a clearer story than the CEO reviews. Vaping went from a moderate concern (rated 10 in FY22) to the Group's largest single risk (25 in FY24 and FY25), even as it remained the largest profit pool. Other risks moved in interesting ways too.
Vaping risk doubled, then doubled again. In FY22 the discussion was about long-term health studies and product innovation — risk scored 10. In FY23, with the disposable-vape debate intensifying, the score jumped to 20. By FY24 the disposables ban was inevitable, the marketing-restrictions Bill was being drafted, and an excise duty had been announced — the score hit the maximum of 25, where it stayed in FY25 even after diversification reduced vape's share of the business.
What got safer. Raw material prices (whey, predominantly) were rated 16 in FY22 when prices were near 20-year highs; by FY24 they had retreated and the score fell to 6. Currency risk fell as more revenue moved to UK-domiciled brands. The single-site risk eased once the second Trafford Park warehouse (Ark) opened in FY24, then partially returned in FY25 as Clearly Drinks (Sunderland) and Typhoo (new UK plant) added geographies.
What got newly visible. Health & Safety risk rose from 9 to 12 in FY25 with the Group "now operat[ing] manufacturing from multiple sites … overseen by a single Health & Safety Manager." IT risk ticked up to 16 because the Typhoo acquisition "enhanced [the Group's] public profile, potentially making a more visible target for cyber attack" — a candid disclosure.
How They Handled Bad News
There have been three real disappointments since IPO: the FY23 Lighting collapse, the dividend-policy reversal, and the disposable-vape ban. The handling has been different in each case.
The Lighting collapse (FY22→FY23). Lighting revenue fell 43% from £27.0m to £15.4m as retailers worked off pandemic-era stockpiles. Management was direct about it, attributing the fall to a "temporary slowdown" and customer overstocking — and crucially noted that all listings and all customer relationships had been retained. The H1 FY23 print (Adj EBITDA -20% YoY, EPS -52%) was not sugar-coated. Recovery was promised across FY24-FY25; FY24 delivered a modest +7% rebound, but FY25 lighting fell again (-6% combined with batteries). The "temporary" framing was honest about FY23 but optimistic about the eventual ceiling.
The dividend cut. At IPO in February 2021, management promised "an aggregate annual amount equivalent to approximately 50% of net profits". By July 2022, eighteen months later, the policy was rebased to ~25%. The reframing in the FY23 H1 statement — "Supreme announced that it was revising its dividend policy to 25%" — was placed in the cash-flow notes rather than highlighted as a strategic shift. This is the cleanest example of a quietly walked-back IPO promise: it was not labelled as such.
The disposable-vape ban. In FY24 management was already pivoting language ("the potential short-term nature of this opportunity given the uncertainty of future legislation"), telegraphing the FY25 transition before it arrived. By the time the 1 June 2025 ban hit, management had already bought Clearly Drinks (June 2024) and Typhoo (November 2024), reducing vape concentration. The FY25 commentary was matter-of-fact: disposable revenue down £16.6m, no extensive stock provisions needed, transition managed. This was the most disciplined response — the diversification was telegraphed and executed in advance, even if the language about "an opportunity to reframe the commercial positioning" reads like a euphemism for "the regulator just took out a third of our revenue."
Guidance Track Record
Below is every promise or guidance number that meaningfully shaped the share-price reaction or capital-allocation decisions, with how it ended.
Pattern. When the in-house levers are working (FY22, FY24, FY25 EBITDA), management beats. When the macro turns against them (FY23, FY25 revenue), they miss. Their explanations have generally been honest about what went wrong. The promises that have aged worst are not the financial ones — they are the strategic-language ones (the dividend policy, international expansion, "longer-term plans" for individual brands).
Credibility score (1-10)
Basis: Strong M&A execution; weak narrative discipline.
6/10 — earned upward, deserved downward. The team has compounded book value, made seven small acquisitions at attractive multiples (Sci-MX 9-month payback; Cuts Ice 4-month payback; Liberty Flights tracking to a 4-year payback; Clearly Drinks accretive in year one; Typhoo a £4.1m bargain-purchase gain), and called the disposable-vape ban early enough to diversify ahead of it. That is a 7+ on execution. But the dividend rebase, the FY23 miss, the pattern of "longer-term plans" being abandoned when better opportunities arise, and the quiet disappearance of multiple stated strategic priorities pull the number down. The CEO sacrificing his salary in H2 FY23 to fund cost-of-living pay rises pulled it back up by half a notch.
What the Story Is Now
The current pitch — confirmed in the H1 FY26 results in November 2025 — is that Supreme is no longer a vaping company that does some other things. It is a vertically-integrated FMCG roll-up where vape will fall to roughly half of revenue, with the other half coming from Drinks & Wellness (Clearly Drinks, Typhoo, SlimFast, Sci-MX) and a smaller Electricals & Household pillar (batteries, lighting, 1001). The platform — Manchester manufacturing, Ark distribution, ~10,000 retail outlets — is the thesis. The brands fit through it.
Read this if nothing else. The bull case for Supreme is that the team buys distressed UK consumer brands at low multiples and runs them through a working distribution platform. That case is reasonable and partially earned. The bear risk is that this is a serial acquirer disguised as an organic-growth story — H1 FY26 reveals that £4.2m of the £19.6m revenue growth came from organic; the rest was M&A. The story now is "compound capital through opportunistic deals", not "scale a great vaping franchise". Both can work — but they are different stories, and the second one tends to derate when deals slow.
The single most useful quote from the entire five-year file appears in the FY25 CEO review, as the disposable-vape ban arrives:
"We view the forthcoming levy on vaping as an opportunity to reframe the commercial positioning of our vaping products."
That is exactly the right management-team instinct — when the world reframes against you, reframe with it — and exactly the kind of language a reader should learn to translate. "Reframe the commercial positioning" means "the old positioning no longer works." Investors who hear that as a positive should remember that Supreme's IPO commercial positioning was "leading multi-category FMCG", and within thirty months the dividend policy, the category split, and the strategic priorities had all been reframed too. Supreme is a good business run by a competent operator. It is not the same business it was at IPO, and management's preferred reframing is to change the story rather than to acknowledge that it changed.